Titan Pharmaceuticals Inc (NASDAQ:TTNP) — Market Cap & Net Worth
Market Cap & Net Worth: Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals Inc (NASDAQ:TTNP) has a market capitalization of $6.13 Million ($6.13 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27956 globally and #5515 in its home market, demonstrating a 7.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Titan Pharmaceuticals Inc's stock price $4.61 by its total outstanding shares 1330234 (1.33 Million). Analyse Titan Pharmaceuticals Inc (TTNP) cash conversion ratio to see how efficiently the company converts income to cash.
Titan Pharmaceuticals Inc Market Cap History: 2015 to 2025
Titan Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $21.26 Billion to $6.13 Million (-55.77% CAGR).
Index Memberships
Titan Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #823 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2645 of 3165 |
Weight: Titan Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Titan Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Titan Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10974.43x
Titan Pharmaceuticals Inc's market cap is 10974.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $21.26 Billion | $1.67 Million | -$11.28 Million | 12724.39x | N/A |
| 2016 | $19.16 Billion | $15.06 Million | $5.13 Million | 1271.51x | 3730.35x |
| 2017 | $6.35 Billion | $215.00K | -$14.31 Million | 29512.63x | N/A |
| 2018 | $1.07 Billion | $5.91 Million | -$9.02 Million | 180.67x | N/A |
| 2019 | $154.92 Million | $3.61 Million | -$16.09 Million | 42.90x | N/A |
| 2020 | $87.53 Million | $4.84 Million | -$20.73 Million | 18.09x | N/A |
| 2021 | $27.14 Million | $1.53 Million | -$8.11 Million | 17.78x | N/A |
| 2022 | $20.83 Million | $60.00K | -$10.18 Million | 347.24x | N/A |
| 2023 | $10.97 Million | $1.00K | -$5.57 Million | 10974.43x | N/A |
Competitor Companies of TTNP by Market Capitalization
Companies near Titan Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Titan Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Titan Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Titan Pharmaceuticals Inc's market cap moved from $21.26 Billion to $ 6.13 Million, with a yearly change of -55.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $6.13 Million | +41.41% |
| 2024 | $4.34 Million | -60.48% |
| 2023 | $10.97 Million | -47.32% |
| 2022 | $20.83 Million | -23.23% |
| 2021 | $27.14 Million | -69.00% |
| 2020 | $87.53 Million | -43.50% |
| 2019 | $154.92 Million | -85.49% |
| 2018 | $1.07 Billion | -83.17% |
| 2017 | $6.35 Billion | -66.88% |
| 2016 | $19.16 Billion | -9.91% |
| 2015 | $21.26 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Titan Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.13 Million USD |
| MoneyControl | $6.13 Million USD |
| MarketWatch | $6.13 Million USD |
| marketcap.company | $6.13 Million USD |
| Reuters | $6.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.